27.6 C
Friday, February 3, 2023

Flu testing still seeing disruption but benefiting from rising ‘multi-parameter’ diagnostics testing for both COVID-19 and flu, says GlobalData

Diagnostics that can test for both COVID-19 and flu have quickly replaced tests that indicate for flu alone, according to GlobalData. The leading data and analytics company notes that these ‘multi-parameter’ tests now comprise a global market worth $1.54bn.

Chris Onderisin, Medical Devices Analyst at GlobalData, comments: “Multi-parameter tests with the ability to diagnose both COVID-19 and influenza have seen a tremendous rise in value – especially considering this specific market was non-existent a mere two years ago. This is only good news for flu testing, which saw significant disruption throughout the COVID-19 pandemic.”

Traditional influenza testing volumes in US hospitals saw strong growth between 2015 and 2019, but the most recent flu season saw testing decline by nearly 67% over the same period for tests developed prior to 2020. Multi-parameter tests now make up nearly 84% of diagnostic tests for influenza in US hospitals.

Onderisin continues: “Successful public vaccination campaigns for COVID-19 have effectively ended many of the public health measures that also curbed the spread of flu last season. Multi-parameter testing will continue to aid clinicians in guiding treatment options this flu season while also supporting COVID-19 diagnoses. GlobalData expects global sales for new COVID-19 fighting drugs Lagevrio and Paxlovid to exceed $15.6bn in 2022. Receiving an accurate diagnosis is essential for drugs such as these, particularly with new antivirals arriving to market that can drastically improve outcomes following infection.”

The COVID-19 pandemic has also accelerated the regulatory approval and laboratory adoption of testing platforms that offer multiplex respiratory panels – tests that can differentiate between multiple infectious agents from a single sample. For clinicians, such tests can provide confidence and additional peace of mind when ruling out potential infection from COVID-19.

Onderisin adds: “In vitro diagnostic companies are in the process of developing rapid antigen-detection tests that include both COVID-19 and influenza, mirroring the transition to point-of-care and home-testing observed for COVID-19 tests in 2021. These differentiated multiplex tests will likely play an important role in diagnostics for years to come.”

Related Articles


Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.

- Advertisement -


- Advertisement -

Latest Articles

- Advertisement -
- Advertisement -